Alivus Life Sciences Ltd (NSE: ALIVUS, BSE: 543322) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹16,073 Cr, it ranks #430 by market cap among the 6,137 Indian listed companies on FinBizNet, and #3 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹1,250.60 (as of 25 Oct 2026), the share price is 16.3% below its 52-week high of ₹1,493.80 and 52.7% above its 52-week low of ₹819.00. The share price is up 33.8% over one year and up 13.6% over three months.
| Current Price | ₹1,250.60 |
|---|---|
| Market Cap | ₹16,073 Cr |
| NSE Symbol | ALIVUS |
| BSE Code | 543322 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 27.7 |
| Return on Equity | 18.36% |
| Return on Assets | 12.21% |
| 52-Week Range | ₹819.00 – ₹1,493.80 |
| 1-Year Price Change | +33.8% |
| 3-Month Price Change | +13.6% |
| Beta (1Y) | 0.34 |
| Dividend Yield | 0.39% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.alivus.com |
| Revenue | ₹640 Cr |
|---|---|
| Net Profit | ₹160 Cr |
| Net Margin | 25.0% |
| EPS (Basic) | ₹13.04 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 a
1. Active Pharmaceutical Ingredient (API)-This segment develops and manufactures non-commoditized active pharmaceutical ingredients for various chronic therapeutic, gastro-intestinal disorder, anti-infective, and other therapeutic areas. 2. Other Operating Revenue-This segment develops and manufactures active pharmaceutical ingredients in chronic therapeutic areas, such as cardiovascular disease, central nervous system disease, pain management, and diabetes. 3. CDMO-This segment provides CDMO services to a range of multinational and specialty pharmaceutical companies. 4. Generic API-NA
1. Active Pharmaceutical Ingredient (API)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Infinium Pharmachem Limited | ₹475 Cr | 37.6 | — | — | +13.5% |
Listed by market capitalisation. Ratios are shown for context only.
Alivus Life Sciences Ltd is trading at ₹1,250.60, with a market capitalisation of ₹16,073 Cr.
Alivus Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Alivus Life Sciences Ltd has a P/E of 27.7 and a return on equity of 18.36%.
Alivus Life Sciences Ltd is listed on the NSE under the symbol ALIVUS and on the BSE under the scrip code 543322.
Alivus Life Sciences Ltd's share price is up 33.8% over one year and up 13.6% over three months. Its 52-week range is ₹819.00 to ₹1,493.80.
In Q1 FY27, Alivus Life Sciences Ltd reported revenue of ₹640 Cr and net profit of ₹160 Cr, with basic EPS of ₹13.04 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.